<article article-type="review-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12787173</article-id><article-id pub-id-type="pmcid-ver">PMC12787173.1</article-id><article-id pub-id-type="pmcaid">12787173</article-id><article-id pub-id-type="pmcaiid">12787173</article-id><article-id pub-id-type="pmid">41516355</article-id><article-id pub-id-type="doi">10.3390/ijms27010482</article-id><article-id pub-id-type="publisher-id">ijms-27-00482</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Human Leukocyte Antigen (<italic toggle="yes">HLA</italic>) Signatures and Idiosyncratic Drug-Induced Liver Injury</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Onaciu</surname><given-names initials="A">Alexia</given-names></name><xref ref-type="aff" rid="af1-ijms-27-00482">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Grama</surname><given-names initials="A">Alina</given-names></name><xref ref-type="aff" rid="af2-ijms-27-00482">2</xref><xref ref-type="aff" rid="af3-ijms-27-00482">3</xref><xref ref-type="corresp" rid="c1-ijms-27-00482">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Agoșton</surname><given-names initials="Ș">Ștefan</given-names></name><xref ref-type="aff" rid="af1-ijms-27-00482">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mititelu</surname><given-names initials="A">Alexandra</given-names></name><xref ref-type="aff" rid="af2-ijms-27-00482">2</xref><xref ref-type="aff" rid="af3-ijms-27-00482">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mariş</surname><given-names initials="B">Bianca</given-names></name><xref ref-type="aff" rid="af2-ijms-27-00482">2</xref><xref ref-type="aff" rid="af3-ijms-27-00482">3</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4034-5471</contrib-id><name name-style="western"><surname>Ştefănescu</surname><given-names initials="H">Horia</given-names></name><xref ref-type="aff" rid="af4-ijms-27-00482">4</xref><xref ref-type="aff" rid="af5-ijms-27-00482">5</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4931-1219</contrib-id><name name-style="western"><surname>Pop</surname><given-names initials="TL">Tudor Lucian</given-names></name><xref ref-type="aff" rid="af2-ijms-27-00482">2</xref><xref ref-type="aff" rid="af3-ijms-27-00482">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>DeMorrow</surname><given-names initials="S">Sharon</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-27-00482"><label>1</label>Faculty of Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania</aff><aff id="af2-ijms-27-00482"><label>2</label>2nd Pediatric Discipline, Department of Mother and Child, Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania</aff><aff id="af3-ijms-27-00482"><label>3</label>2nd Pediatric Clinic, Emergency Clinical Hospital for Children, 400370 Cluj-Napoca, Romania</aff><aff id="af4-ijms-27-00482"><label>4</label>“Prof. Dr. Octavian Fodor” Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania</aff><aff id="af5-ijms-27-00482"><label>5</label>Department of Internal Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania</aff><author-notes><corresp id="c1-ijms-27-00482"><label>*</label>Correspondence: <email>gramaalina16@elearn.umfcluj.ro</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>27</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">503380</issue-id><elocation-id>482</elocation-id><history><date date-type="received"><day>23</day><month>11</month><year>2025</year></date><date date-type="rev-recd"><day>28</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>01</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>10</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-11 04:25:13.993"><day>11</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2026 by the authors.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">Creative Commons Attribution (CC BY) license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="ijms-27-00482.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><p>Drug-induced liver injury (DILI) remains one of the most challenging adverse drug reactions in clinical practice, particularly in its idiosyncratic form, which is not dose-dependent and is largely driven by host-specific immune and genetic factors. Recent genomic studies have revealed strong associations between certain human leukocyte antigen (<italic toggle="yes">HLA</italic>) alleles and susceptibility to DILI, supporting an immunogenetic mechanism in which drug or metabolite–protein adducts act as neoantigens, triggering aberrant T-cell activation and hepatocellular injury. This review summarizes current evidence on the contribution of <italic toggle="yes">HLA</italic> polymorphisms to the pathogenesis of idiosyncratic DILI, highlighting allele-specific risk patterns, such as <italic toggle="yes">HLA</italic>-<italic toggle="yes">B*57:01</italic> associated with flucloxacillin, <italic toggle="yes">HLA</italic>-<italic toggle="yes">DRB1*15:01–DQB1*06:02</italic> in amoxicillin–clavulanate, and <italic toggle="yes">HLA-B*35:02</italic> in minocycline-induced liver injury. Furthermore, ethnic variability and allele-haplotype interactions are discussed as potential modulators of susceptibility and clinical phenotype. By integrating genetic and immunological insights, the identification of <italic toggle="yes">HLA</italic> signatures offers promising tools for precision medicine, enabling earlier identification of at-risk individuals and improved prevention of severe hepatotoxic reactions.</p></abstract><kwd-group><kwd>drug-induced liver injury</kwd><kwd><italic toggle="yes">HLA</italic> polymorphisms</kwd><kwd>adaptive immune response</kwd><kwd>idiosyncratic drug reactions</kwd></kwd-group><funding-group><award-group><funding-source>Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca</funding-source><award-id>32152/14/16.12.2024</award-id></award-group><funding-statement>This research was funded by Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania, Grant number 32152/14/16.12.2024.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-ijms-27-00482" sec-type="intro"><title>1. Introduction</title><p>Drug-Induced Liver Injury (DILI) is an acute or chronic liver injury secondary to exposure to certain xenobiotics, mainly pharmaceutical drugs. Depending on the type of toxic agent, hepatotoxic reactions can be classified as either intrinsic or idiosyncratic. Intrinsic hepatotoxicity is a dose-dependent toxicity that appears shortly after exposure, due to exceeding the liver detoxification capacity by administering overdoses. Histological findings are characterized by hepatic necrosis or steatosis, which may result from the direct action of the chemical substance or its metabolites (direct hepatotoxicity) or from disruption of intracellular metabolic processes (indirect toxicity). Acetaminophen is the prototype agent of direct hepatotoxicity, whereas the toxicity of Amanita phalloides is often indirect, by inhibiting RNA polymerase II and impairing protein synthesis [<xref ref-type="bibr" rid="B1-ijms-27-00482">1</xref>,<xref ref-type="bibr" rid="B2-ijms-27-00482">2</xref>]. The liver functions as the primary organ of biotransformation, converting lipophilic xenobiotics into hydrophilic metabolites mainly through cytochrome P450–mediated oxidative pathways, thereby facilitating their excretion via renal or biliary routes [<xref ref-type="bibr" rid="B3-ijms-27-00482">3</xref>]. Mechanisms of hepatotoxicity predominantly involve the hepatic biotransformation of drugs into reactive metabolites, which may exceed the liver’s intrinsic detoxification and antioxidant capacities. These metabolites can cause hepatocyte necrosis through oxidative stress or mitochondrial dysfunction and activation of intracellular signaling networks and programmed cell death [<xref ref-type="bibr" rid="B4-ijms-27-00482">4</xref>]. These reactive intermediates trigger an immunologically mediated response by initiating immune dysregulation, loss of self-tolerance, and the formation of neoantigens [<xref ref-type="bibr" rid="B5-ijms-27-00482">5</xref>].</p><p>Idiosyncratic DILI is a condition in which liver damage occurs because of exposure to pharmaceutical drugs, herbal products, or other xenobiotics, independent of dose. Usually, toxicity results from individual genetic factors, immune-mediated mechanisms, or metabolic variations that influence a patient’s susceptibility to hepatotoxicity [<xref ref-type="bibr" rid="B1-ijms-27-00482">1</xref>]. Host-specific immune factors, particularly specific human leukocyte antigen (<italic toggle="yes">HLA</italic>) haplotypes, are involved in this relation between genetic susceptibility and aberrant immune activation, highlighting the complexity of idiosyncratic DILI and contributing to the ongoing challenges in its early diagnosis and prevention [<xref ref-type="bibr" rid="B1-ijms-27-00482">1</xref>,<xref ref-type="bibr" rid="B6-ijms-27-00482">6</xref>]. In idiosyncratic toxicity, genetic factors play a significant role. Mutations in genes encoding enzymes involved in Phase I and Phase II hepatic metabolism increase susceptibility to toxic liver injury [<xref ref-type="bibr" rid="B5-ijms-27-00482">5</xref>,<xref ref-type="bibr" rid="B7-ijms-27-00482">7</xref>]. The best example of metabolic idiosyncratic hepatotoxicity is isoniazid, whose toxicity is influenced by genetic mutations that affect the activity of N-acetyltransferase 2, the enzyme responsible for its hepatic metabolism.</p><p>Both types of DILI, intrinsic and idiosyncratic, share common molecular features, including disruption of calcium homeostasis, damage to cellular or canalicular membranes, metabolic bioactivation, triggering of autoimmunity, and mitochondrial impairment, leading to hepatocyte apoptosis and necrosis [<xref ref-type="bibr" rid="B3-ijms-27-00482">3</xref>].</p><p>Multiple host-related factors (including age, genetic predisposition, and autoimmune activation) and environmental factors (exposure to industrial chemicals such as carbon tetrachloride, toxins such as aflatoxin, and pollutants) can trigger DILI [<xref ref-type="bibr" rid="B8-ijms-27-00482">8</xref>]. Although advanced age is generally associated with an increased susceptibility to hepatotoxicity, children may experience more severe liver injury after exposure to specific xenobiotics such as valproic acid or aspirin. This increased vulnerability in the pediatric population may be attributed to immature hepatic metabolic capacity. The result is reduced expression of drug transport proteins and increased accumulation of toxic intermediates, exacerbating hepatocellular damage [<xref ref-type="bibr" rid="B1-ijms-27-00482">1</xref>,<xref ref-type="bibr" rid="B2-ijms-27-00482">2</xref>,<xref ref-type="bibr" rid="B6-ijms-27-00482">6</xref>].</p><p>The major histocompatibility complex (MHC) consists of a group of genes located on the short arm of chromosome 6 that encode certain membrane glycoproteins. There are three known classes of <italic toggle="yes">HLA</italic>: Class I (<italic toggle="yes">HLA-A</italic>, <italic toggle="yes">-B</italic>, and <italic toggle="yes">-C</italic>), Class II (<italic toggle="yes">HLA-DR</italic>, <italic toggle="yes">-DP</italic>, <italic toggle="yes">-DQ</italic>), and Class III (including tumor necrosis factor, some cytokines, interleukins, and complement components). Children’s predisposition to develop autoimmune hepatitis (AIH) is associated with Class II <italic toggle="yes">HLA</italic> genes, specifically the DRB1 locus. This gene encodes proteins involved in the immune system that distinguish self-proteins from non-self proteins, such as proteins of bacterial or viral origin [<xref ref-type="bibr" rid="B5-ijms-27-00482">5</xref>]. <italic toggle="yes">HLA</italic> molecules play a critical role in the host immune response by presenting non-self antigens to CD4<sup>+</sup> T helper lymphocytes (Th1 and Th2), thereby eliciting both humoral and cell-mediated immune responses [<xref ref-type="bibr" rid="B5-ijms-27-00482">5</xref>].</p><p>Current evidence supports the involvement of the MHC in the initiation of idiopathic AIH. Specifically, the alleles <italic toggle="yes">HLA-DRB1*03:01</italic>, <italic toggle="yes">DRB3*01:01</italic>, and <italic toggle="yes">DRB1*04:01</italic>, which encode the <italic toggle="yes">HLA-DR3</italic>, <italic toggle="yes">DR52</italic>, and <italic toggle="yes">DR4</italic> molecules, respectively, are well known for their role in triggering type 1 AIH in European and North American populations. Furthermore, the role of certain drugs in triggering autoimmune diseases is also recognized, as they may induce latent immunity [<xref ref-type="bibr" rid="B9-ijms-27-00482">9</xref>,<xref ref-type="bibr" rid="B10-ijms-27-00482">10</xref>]. The presence of <italic toggle="yes">HLA</italic>-<italic toggle="yes">DRB1*03:01</italic> or <italic toggle="yes">04:01</italic> alleles supports the diagnosis of idiopathic AIH, whereas the detection of DILI-associated alleles favors drug-induced AIH (DI-AIH). Notably, <italic toggle="yes">HLA</italic>-<italic toggle="yes">DRB1*15:01</italic>, a known DILI risk allele, is less frequently observed in AIH than in healthy individuals, underscoring the utility of genetic testing to distinguish between these conditions [<xref ref-type="bibr" rid="B11-ijms-27-00482">11</xref>]. Associations have also been identified between specific <italic toggle="yes">HLA</italic> class II alleles and the pattern of liver injury in drug-induced hepatotoxicity. In particular, the alleles <italic toggle="yes">HLA</italic>-<italic toggle="yes">DRB1*15</italic> and <italic toggle="yes">HLA</italic>-<italic toggle="yes">DQB1*06</italic> have been linked to cholestatic features, whereas <italic toggle="yes">HLA</italic>-<italic toggle="yes">DRB1*07</italic> and <italic toggle="yes">HLA</italic>-<italic toggle="yes">DQB1*02</italic> appear to confer a protective effect. Nevertheless, not all individuals carrying these alleles develop hepatotoxicity, suggesting that additional host, metabolic, or environmental factors contribute to disease susceptibility [<xref ref-type="bibr" rid="B12-ijms-27-00482">12</xref>].</p><p>This narrative review analyses current evidence on <italic toggle="yes">HLA</italic> involvement in the genetic predisposition to DILI, providing a preliminary understanding of a potential key tool for advancing predictive and precision medicine in hepatology.</p></sec><sec id="sec2-ijms-27-00482"><title>2. Correlations Between DILI and AIH</title><p>In genetically predisposed individuals, the immune response against hepatic structures may be initiated following viral infection or exposure to certain drugs or toxic agents. These exposures can promote the formation of drug–protein adducts (neoantigens), which determine autoimmune-like reactions leading to DI-AIH or immune-mediated liver injury. This immune-mediated process involves B cell activation and the production of autoantibodies, which initiate hepatic parenchymal inflammatory cascades, leading to portal and periportal inflammation, interface hepatitis, and, in severe cases, hepatocellular necrosis [<xref ref-type="bibr" rid="B13-ijms-27-00482">13</xref>]. The processes share many clinical and histopathological features with idiopathic AIH, making differential diagnosis difficult [<xref ref-type="bibr" rid="B13-ijms-27-00482">13</xref>].</p><p>After a xenobiotic enters the body, the liver’s metabolic system converts it into non-toxic, water-soluble metabolites, which are then eliminated. In some cases, this bioactivation process generates reactive intermediates that covalently bind to cellular macromolecules (such as proteins and lipids), forming drug–protein adducts (hapten–carrier complexes). These modified structures are recognized by the immune system as neoantigens, causing immune-mediated reactions. The responses are classical hypersensitivity reactions, directed against the xenobiotic itself, or autoimmune-like reactions, in which hepatocytes become unintended targets of the adaptive immune response [<xref ref-type="bibr" rid="B14-ijms-27-00482">14</xref>]. An example is halothane-induced hepatotoxicity, which represents a type II hypersensitivity reaction [<xref ref-type="bibr" rid="B5-ijms-27-00482">5</xref>]. During halothane metabolism via cytochrome P450 2E1 (CYP2E1), reactive intermediates, such as trifluoroacetylated species, are generated, which covalently bind to hepatic proteins, forming neoantigenic complexes. It will trigger the production of anti-trifluoroacetyl and anti-CYP2E1 autoantibodies against hepatocytes, leading to complement activation, cellular cytotoxicity, and hepatic necroinflammation [<xref ref-type="bibr" rid="B15-ijms-27-00482">15</xref>,<xref ref-type="bibr" rid="B16-ijms-27-00482">16</xref>].</p><p>Correlations between hepatic toxicity and AIH are well established. Drugs can cause toxic hepatitis with autoimmune features or may act as triggers for AIH [<xref ref-type="bibr" rid="B17-ijms-27-00482">17</xref>]. Both conditions can present similar clinical, laboratory, and histological features. Differentiating idiosyncratic hepatotoxicity with autoimmune features from true AIH represents a real challenge for clinicians, especially when specific antibodies are not detected or immunoglobulin G levels remain normal. Liver biopsy and histological examination could distinguish between these two conditions. The presence of interface hepatitis, periportal inflammation, or emperipolesis is suggestive of idiopathic AIH. In contrast, toxicity is typically associated with an increased number of neutrophils in the portal vein spaces [<xref ref-type="bibr" rid="B17-ijms-27-00482">17</xref>]. Three main forms of immune-mediated drug-induced liver pathology (DI-AILD) are currently described: autoimmune hepatitis with overlapping drug-induced liver injury (AIH with DILI), drug-induced autoimmune hepatitis (DI-AIH), and immune-mediated DILI (IM-DILI) [<xref ref-type="bibr" rid="B10-ijms-27-00482">10</xref>]. Distinguishing among these is important, especially since AIH typically requires long-term immunosuppressive therapy. In children, this approach carries potential risks, not only for growth and development but also for social and cognitive well-being. In contrast, idiosyncratic DILI generally does not demand such intensive treatment [<xref ref-type="bibr" rid="B10-ijms-27-00482">10</xref>]. Before confirming a diagnosis of idiopathic AIH triggered by drugs or identifying a specific drug as the cause of IM-DILI, genetic predisposition and <italic toggle="yes">HLA</italic>-<italic toggle="yes">DR</italic> class II typing could be useful. Although the MHC is thought to contribute to autoimmune liver responses, its role in drug-induced toxicity is less defined. Also, DILI itself may act as a trigger for AIH in susceptible individuals. <italic toggle="yes">HLA</italic>-<italic toggle="yes">DRB1*03:01</italic> and <italic toggle="yes">HLA</italic>-<italic toggle="yes">DRB1*04:01</italic> alleles, which represent well-established genetic risk factors for idiopathic AIH, do not significantly increase susceptibility to DI-AIH. This finding suggests that DI-AIH and classical AIH, while sharing immunopathological features, may involve distinct genetic and mechanistic pathways [<xref ref-type="bibr" rid="B18-ijms-27-00482">18</xref>].</p></sec><sec id="sec3-ijms-27-00482"><title>3. Present Evidence on <italic toggle="yes">HLA</italic> Associations with DILI (<xref ref-type="table" rid="ijms-27-00482-t001">Table 1</xref>)</title><sec id="sec3dot1-ijms-27-00482"><title>3.1. Non-Steroidal Anti-Inflammatory Drug (NSAIDs)</title><p>Immunologic DILI is an immune-mediated hypersensitivity reaction to a specific xenobiotic that predominantly occurs in people with an inadequate adaptive immune response. This type of toxicity depends on the host’s immune system, including <italic toggle="yes">HLA</italic>, as well as the chemical properties of the xenobiotic, its metabolites, or reactive haptens [<xref ref-type="bibr" rid="B19-ijms-27-00482">19</xref>,<xref ref-type="bibr" rid="B20-ijms-27-00482">20</xref>]. Often, this type of hepatotoxicity is accompanied by extrahepatic symptoms, such as skin rashes and eosinophilia, and its severity is directly related to the individual’s immune tolerance. In a study by Bonkovsky HL, diclofenac was the most frequently implicated agent in NSAID-induced hepatotoxicity, accounting for more than 90%, and ibuprofen accounted for less than 10%. For both drugs, a close association with genetic predisposition has been identified. <italic toggle="yes">HLA-DRB1*04:03</italic> increased the hepatotoxicity risk of those drugs by eightfold and has been associated with a severe phenotype, often co-occurring with <italic toggle="yes">HLA-DQA1*03:01</italic>. These associations were consistent across populations and predominantly driven by acetic acid derivative NSAIDs [<xref ref-type="bibr" rid="B21-ijms-27-00482">21</xref>]. In addition, another allele, <italic toggle="yes">HLA-B*35:03</italic>, was linked to a higher risk of NSAID-related liver injury, mainly in non-Hispanic White and Hispanic populations, where it is much more common than in non-Hispanic Black individuals [<xref ref-type="bibr" rid="B21-ijms-27-00482">21</xref>].</p><p>In contrast, the <italic toggle="yes">HLA-A*02:01</italic> allele was associated with a significant, independent protective effect against NSAID-induced liver injury, most evident in cases involving diclofenac. These findings support a dual model of genetic susceptibility and protection, in which <italic toggle="yes">HLA-DRB1*04:03</italic> predisposes and <italic toggle="yes">HLA-A*02:01</italic> protects against NSAID-induced hepatotoxicity [<xref ref-type="bibr" rid="B21-ijms-27-00482">21</xref>]. Even though ibuprofen is a widely prescribed, over-the-counter drug, it has been generally thought to be safe regarding liver toxicity. However, cases of ibuprofen-induced DILI arise, while the Spanish and Latin American DILI registries found higher than expected rates [<xref ref-type="bibr" rid="B22-ijms-27-00482">22</xref>]. Reports of <italic toggle="yes">HLA</italic> susceptibility alleles for ibuprofen-induced DILI are scarce, but Gui et al. identified <italic toggle="yes">HLA-B*58:01</italic> in a pediatric patient who developed Stevens-Johnson syndrome and liver injury following ibuprofen treatment [<xref ref-type="bibr" rid="B23-ijms-27-00482">23</xref>].</p></sec><sec id="sec3dot2-ijms-27-00482"><title>3.2. Nitrofurans and Tetracyclins</title><p>The potential of nitrofurans and some tetracyclines to induce AIH in genetically susceptible individuals is already known. A high titer of antinuclear autoantibodies (ANA) was found in nitrofurantoin (52%) and minocycline (57%) DILI cases [<xref ref-type="bibr" rid="B24-ijms-27-00482">24</xref>]. The <italic toggle="yes">HLA-B*35:02</italic> allele has been identified as a potential genetic risk factor for minocycline-induced DILI [<xref ref-type="bibr" rid="B25-ijms-27-00482">25</xref>]. This association, first detected through genome-wide association studies (GWAS) and subsequently confirmed by sequence-based <italic toggle="yes">HLA</italic> typing, suggests that drug-specific genetic susceptibility to DILI may involve both Class I and Class II <italic toggle="yes">HLA</italic> alleles. The <italic toggle="yes">HLA-B*35:02</italic> allele is rare in the general population, with an estimated frequency of approximately 0.3% in Caucasians and less than 0.1% in African Americans. Importantly, this relationship does not appear to reflect confounding by indication, as previous GWAS in acne patients (the main population receiving minocycline) have shown no association between this allele and acne [<xref ref-type="bibr" rid="B25-ijms-27-00482">25</xref>]. Affected individuals present with autoimmune-like features (including positive autoantibody profiles and hypergammaglobulinemia, at the time of diagnosis) and liver biopsy findings often reveal interface hepatitis and plasma cell infiltration, closely resembling AIH. Approximately half of the patients received corticosteroid therapy with liver injury remission, 24% progressed to chronic DILI, with no cases with liver transplantation or fatal evolution. This suggests that <italic toggle="yes">HLA-B*35:02</italic> may predispose to a slow evolution, towards chronicity [<xref ref-type="bibr" rid="B25-ijms-27-00482">25</xref>].</p><p>Nitrofurantoin-induced liver injury may occur after only a few days of treatment, but it is more commonly seen after prolonged use, more than one year. Nitrofurantoin hepatotoxicity is associated with the <italic toggle="yes">HLA-DRB1*11:04</italic> allele, which was observed approximately 4 times more frequently in American patients of European descent who developed hepatotoxicity than in the control population [<xref ref-type="bibr" rid="B26-ijms-27-00482">26</xref>]. This allele was present exclusively in individuals who had long-term exposure to nitrofurantoin, suggesting a potential exposure-dependent genetic predisposition. Chronic exposure is frequently associated with autoimmune-like features and histological evidence of chronic hepatitis and fibrosis, often necessitating corticosteroid therapy. Long-term users of nitrofurantoin are therefore at risk of significant morbidity and mortality, and regular monitoring of ALT every 3–6 months is recommended in patients receiving extended therapy [<xref ref-type="bibr" rid="B26-ijms-27-00482">26</xref>]. In contrast, cases of liver injury following short-term nitrofurantoin therapy showed a higher prevalence of the extended haplotype <italic toggle="yes">HLA-A*01:01–B*08:01–C*07:01</italic>. These <italic toggle="yes">HLA</italic> markers, which correlated with treatment duration, could serve as markers to identify patients at risk of nitrofurantoin hepatotoxicity [<xref ref-type="bibr" rid="B26-ijms-27-00482">26</xref>].</p><p>Analysis of data from the Drug-Induced Liver Injury Network (DILIN) demonstrated that most cases of DILI associated with nitrofurantoin or minocycline, and approximately half of those linked to methyldopa or hydralazine, exhibited autoimmune features resembling AIH. However, these autoimmune manifestations generally diminished as hepatic injury resolved and were not associated with the classical <italic toggle="yes">HLA</italic> alleles known to confer susceptibility to AIH [<xref ref-type="bibr" rid="B27-ijms-27-00482">27</xref>].</p></sec><sec id="sec3dot3-ijms-27-00482"><title>3.3. Flucloxacillin</title><p>The increased risk of hepatotoxicity in some patients after taking certain medications may be explained by the preferential molecular association of specific drugs or their metabolites with various peptides that bind <italic toggle="yes">HLA</italic> molecules. A good example is flucloxacillin, which is associated with <italic toggle="yes">HLA-B*57:01</italic>, or amoxicillin with <italic toggle="yes">HLA-DRB1*06:02</italic> [<xref ref-type="bibr" rid="B28-ijms-27-00482">28</xref>].</p><p>Flucloxacillin is a common cause of DILI, especially in Northern Europe and Australasia, with incidence rates increasing based on the number of prescriptions and patient age. While most patients recover completely, some may develop chronic liver conditions such as vanishing bile duct syndrome, and in rare cases, a fatal outcome. Initially thought to be caused by impaired drug metabolism, flucloxacillin DILI often presents with hypersensitivity features like rash and fever. The <italic toggle="yes">HLA-B*57:01</italic> gene plays a key role in flucloxacillin-induced DILI; 85% of patients with this condition carry this allele. CD8-positive T cells from individuals with this allele can be activated by flucloxacillin via drug-protein conjugates, though non-hapten pathways have also been proposed [<xref ref-type="bibr" rid="B28-ijms-27-00482">28</xref>]. The allele <italic toggle="yes">HLA-B*57:03</italic>, which is structurally related to <italic toggle="yes">HLA-B*57:01</italic>, has also been associated with an increased risk of flucloxacillin-induced DILI. At the molecular level, the presence of valine at position 97, a residue shared by both <italic toggle="yes">HLA-B*57:01</italic> and <italic toggle="yes">HLA-B*57:03,</italic> appears to be a key determinant of susceptibility, likely influencing the conformation of the peptide-binding groove and the presentation of flucloxacillin-modified self-peptides to cytotoxic T cells [<xref ref-type="bibr" rid="B29-ijms-27-00482">29</xref>].</p><p>CD4<sup>+</sup> and CD8<sup>+</sup> T cells isolated from individuals who developed flucloxacillin-induced DILI were shown to mount antigen-specific immune responses following presentation of flucloxacillin-derived peptides by dendritic cells. Naïve CD8<sup>+</sup> T cells from <italic toggle="yes">HLA-B*57:01</italic>-positive individuals became activated upon exposure to these antigens and expressed chemokine receptors CCR4 and CCR9, enabling migration toward the liver in response to CCL17 and CCL25. The activated T-cell clones secreted interferon-γ (IFN-γ), Th2 cytokines, and cytotoxic mediators, including perforin, granzyme B, and Fas ligand (FasL), which collectively contribute to hepatocellular injury [<xref ref-type="bibr" rid="B29-ijms-27-00482">29</xref>].</p><p>Flucloxacillin was shown to form covalent adducts with lysine residues on serum albumin in a time-dependent manner, and the extent of this binding correlated directly with the magnitude of T-cell activation. The activation of CD8<sup>+</sup> T cells required antigen processing. It was restricted by the presence of <italic toggle="yes">HLA-B*57:01</italic> and the closely related <italic toggle="yes">HLA-B*58:01</italic> alleles, underscoring the critical role of antigen presentation and MHC class I specificity in the pathogenesis of this immune-mediated form of DILI [<xref ref-type="bibr" rid="B29-ijms-27-00482">29</xref>].</p></sec><sec id="sec3dot4-ijms-27-00482"><title>3.4. Amoxicillin-Clavulanate</title><p>The role of <italic toggle="yes">HLA</italic> polymorphisms is particularly evident in amoxicillin–clavulanate-induced liver injury, one of the most frequent causes of idiosyncratic DILI in Western countries. Hautekeete et al. reported that 57% of patients with amoxicillin–clavulanate-associated hepatitis carried the <italic toggle="yes">HLA-DRB1*15:01</italic> allele, compared with only 12% of healthy controls, supporting a strong immunogenetic predisposition. However, subsequent studies have shown that <italic toggle="yes">HLA</italic> genotype alone does not fully predict hepatotoxic risk, reinforcing the multifactorial nature of DILI pathogenesis [<xref ref-type="bibr" rid="B30-ijms-27-00482">30</xref>,<xref ref-type="bibr" rid="B31-ijms-27-00482">31</xref>].</p><p>Donaldson et al. conducted a large, population-based study to define further the <italic toggle="yes">HLA</italic> associations with amoxicillin–clavulanate-induced DILI. Two major findings emerged. First, the study confirmed the previously reported association between the <italic toggle="yes">HLA-DRB1*15:01</italic>–<italic toggle="yes">DQB1*06:02</italic> haplotype and increased susceptibility. Individuals carrying the <italic toggle="yes">DRB1*15:01</italic> allele were significantly over-represented among DILI cases [<xref ref-type="bibr" rid="B31-ijms-27-00482">31</xref>]. Second, a protective effect was identified for the <italic toggle="yes">HLA-DRB1*07</italic> allele family, which was markedly under-represented among affected patients [<xref ref-type="bibr" rid="B31-ijms-27-00482">31</xref>]. As anticipated, all individuals carrying <italic toggle="yes">DRB1*15:01</italic> also possessed the <italic toggle="yes">DQB1*06:02</italic> allele, consistent with strong disequilibrium linkage between these loci. Collectively, these findings confirm a risk-protective dichotomy between <italic toggle="yes">DRB1*15:01–DQB1*06:02</italic> susceptibility and <italic toggle="yes">HLA-DRB1*07</italic> protection in the genetic predisposition to co-amoxiclav hepatotoxicity [<xref ref-type="bibr" rid="B31-ijms-27-00482">31</xref>].</p><p>Hautekeete et al. identified a significant association between the <italic toggle="yes">HLA-DRB1*15:01–DRB5*01:01–DQB1*06:02</italic> haplotype and immunoallergic hepatitis induced by amoxicillin–clavulanate. Through DNA-based <italic toggle="yes">HLA</italic> typing, this haplotype was shown to confer a markedly increased susceptibility to drug-induced liver injury [<xref ref-type="bibr" rid="B32-ijms-27-00482">32</xref>]. Comparison between carriers and non-carriers revealed a distinct pattern of hepatic injury: individuals harboring the haplotype more frequently exhibited cholestatic or mixed forms of hepatitis, whereas none presented with a purely hepatocellular pattern. Other clinical, biochemical, and histopathological characteristics did not differ significantly between the groups. Notably, all patients who displayed extrahepatic hypersensitivity manifestations, including interstitial nephritis, cutaneous rash, or arthritis, and one individual with marked eosinophilia, carried the <italic toggle="yes">DRB1*15:01–DRB5*01:01–DQB1*06:02</italic> haplotype. These findings support a model in which immune-mediated mechanisms, influenced by <italic toggle="yes">HLA</italic> class II genotype, play a central role in amoxicillin–clavulanate–associated hepatotoxicity [<xref ref-type="bibr" rid="B32-ijms-27-00482">32</xref>].</p></sec><sec id="sec3dot5-ijms-27-00482"><title>3.5. Trimethoprim-Sulfamethoxazole</title><p>Trimethoprim–sulfamethoxazole (TMP–SMX)-induced DILI has been linked to distinct <italic toggle="yes">HLA</italic> class I alleles across different ethnic populations. Li et al. reported that <italic toggle="yes">HLA-B*14:01</italic> was significantly associated with TMP-SMX-related hepatotoxicity in European Americans, with carriers exhibiting a 9.2-fold higher risk of liver injury than non-carriers. The allele frequency of <italic toggle="yes">HLA-B*14:01</italic> was approximately 5.5 times greater in affected European American patients than in ethnically matched controls [<xref ref-type="bibr" rid="B33-ijms-27-00482">33</xref>]. In contrast, within the African American subgroup, <italic toggle="yes">HLA-B*35:01</italic> emerged as the principal genetic factor potentially conferring susceptibility to TMP–SMX-induced hepatotoxicity. Although the cohort comprised only 10 African American cases, 50% of affected individuals carried the <italic toggle="yes">HLA</italic>-<italic toggle="yes">B*35:01</italic> allele, a markedly higher frequency than observed in the control population. These findings underscore the ethnic diversity of <italic toggle="yes">HLA</italic>-associated genetic risk for TMP–SMX hepatotoxicity and highlight the need for population-specific pharmacogenetic screening to improve the prediction and prevention of idiosyncratic DILI [<xref ref-type="bibr" rid="B33-ijms-27-00482">33</xref>].</p></sec><sec id="sec3dot6-ijms-27-00482"><title>3.6. Macrolides</title><p>Azithromycin-induced drug-induced liver injury (AZ-DILI) has been associated with the <italic toggle="yes">HLA</italic> class II allele <italic toggle="yes">HLA-DQA1*03:01</italic>, which appears to act as a genetic susceptibility factor for this adverse reaction. The allele was identified at approximately 2.6 times the frequency in AZ-DILI patients compared to the general population [<xref ref-type="bibr" rid="B34-ijms-27-00482">34</xref>]. Among non-Hispanic white individuals, carriers of <italic toggle="yes">DQA1*03:01</italic> seemed to have a lower likelihood of developing chronic liver injury than non-carriers, although this trend requires further confirmation. No association was observed between <italic toggle="yes">DQA1*03:01</italic> and amoxicillin–clavulanate-induced DILI (AC-DILI), suggesting that this genetic marker is specific to azithromycin-related hepatotoxicity [<xref ref-type="bibr" rid="B34-ijms-27-00482">34</xref>]. Further haplotype analysis revealed that the DQ8 haplotype, composed of <italic toggle="yes">HLA-DQA1*03:01–DQB1*03:02</italic>, showed an even stronger correlation with AZ-DILI than <italic toggle="yes">HLA-DQA1*03:01</italic> alone. This finding indicates that the DQ8 haplotype may serve as a more precise and reliable genetic marker for identifying individuals at increased risk of AZ-DILI, supporting its potential use in pharmacogenetic screening strategies [<xref ref-type="bibr" rid="B34-ijms-27-00482">34</xref>].</p><p>Other macrolides have also been involved in DILI pathogenesis. Most evidence points towards erythromycin, with a relative risk (RR) of 3.7 [<xref ref-type="bibr" rid="B35-ijms-27-00482">35</xref>]. The mechanism by which erythromycin causes DILI is different than that of other macrolides, by bile acid accumulation [<xref ref-type="bibr" rid="B36-ijms-27-00482">36</xref>]. Some <italic toggle="yes">HLA</italic> alleles were found to be associated with erythromycin-induced DILI, namely <italic toggle="yes">HLA-A*33:01</italic> and <italic toggle="yes">HLA-A*33:03,</italic> but these are not specific, as they have also been reported for enalapril and sertraline [<xref ref-type="bibr" rid="B37-ijms-27-00482">37</xref>].</p></sec><sec id="sec3dot7-ijms-27-00482"><title>3.7. Fluoroquinolones</title><p>Fluoroquinolones are broad-spectrum antibiotics commonly used in adult infections but are limited in pediatrics due to age-specific adverse reactions and are used to treat multidrug-resistant infections [<xref ref-type="bibr" rid="B38-ijms-27-00482">38</xref>]. DILI can occur with any agent in this class, with no clinical differences among ciprofloxacin, levofloxacin, and moxifloxacin, in correlation with <italic toggle="yes">HLA-DQA1*03:01</italic> and <italic toggle="yes">HLA-B*57:01</italic>, with a high incidence of combined carriage [<xref ref-type="bibr" rid="B39-ijms-27-00482">39</xref>].</p></sec><sec id="sec3dot8-ijms-27-00482"><title>3.8. Antituberculosis Drugs</title><p>Although antituberculosis DILI (ATLI) has been widely studied, no strong, consistent <italic toggle="yes">HLA</italic> associations have been identified. However, Nicoletti et al. reported suggestive evidence that a rare haplotype, <italic toggle="yes">HLA-C12:02–B52:01</italic>, may confer increased susceptibility in certain individuals [<xref ref-type="bibr" rid="B40-ijms-27-00482">40</xref>]. This haplotype was previously associated with Crohn’s disease in Asian populations. <italic toggle="yes">HLA-B*52:01</italic> allele demonstrated a stronger individual association than <italic toggle="yes">HLA-C*12:02</italic>, implying that the <italic toggle="yes">HLA</italic>-<italic toggle="yes">B</italic> locus may play a primary role in mediating this risk. Although only a small number of patients carried the haplotype, its reproducibility across cohorts and known autoimmune associations support its potential relevance. Interestingly, this association was absent in patients receiving isoniazid monotherapy, suggesting that the signal may reflect hepatotoxicity induced by another anti-TB drug, such as pyrazinamide [<xref ref-type="bibr" rid="B3-ijms-27-00482">3</xref>,<xref ref-type="bibr" rid="B40-ijms-27-00482">40</xref>]. Furthermore, while an earlier <italic toggle="yes">HLA</italic> class II typing study in an Indian population reported that the absence of <italic toggle="yes">HLA-DQA1*01:02</italic> and the presence of <italic toggle="yes">HLA-DQB1*02:01</italic> increased the risk of anti-TB DILI, Nicoletti et al. found elevated frequencies of <italic toggle="yes">HLA</italic>-<italic toggle="yes">DQA1*01:03</italic> and <italic toggle="yes">HLA-DQA1*03:01</italic> in their cohort—though these associations were not replicated in European patients, indicating possible ethnic or drug-specific variability in genetic susceptibility [<xref ref-type="bibr" rid="B40-ijms-27-00482">40</xref>]. Chen et al. investigated the potential association between <italic toggle="yes">HLA-DQB1</italic> polymorphisms and the risk of ATLI. No statistically significant differences were initially observed between cases and matched controls [<xref ref-type="bibr" rid="B41-ijms-27-00482">41</xref>]. However, individuals homozygous for <italic toggle="yes">HLA-DQB1*05</italic> appeared more frequently among patients who developed ATLI than in the control group. After adjusting for potential confounding factors, including body weight and the use of hepatoprotective agents, multivariate analysis demonstrated a significant difference in the distribution of the <italic toggle="yes">HLA-DQB1*05/05</italic> genotype between groups [<xref ref-type="bibr" rid="B41-ijms-27-00482">41</xref>]. The odds ratio associated with this genotype remained consistently elevated across all statistical models, suggesting a potential true genetic association between <italic toggle="yes">HLA-DQB1</italic> variants and susceptibility to ATLI. These findings point to a possible role of <italic toggle="yes">HLA-DQB1*05</italic> homozygosity in predisposing certain individuals to anti-TB drug-related hepatotoxicity, although further validation in larger, ethnically diverse cohorts is warranted [<xref ref-type="bibr" rid="B41-ijms-27-00482">41</xref>].</p></sec><sec id="sec3dot9-ijms-27-00482"><title>3.9. Carbamazepine</title><p>The <italic toggle="yes">HLA-A*31:01</italic> allele has recently been investigated as a potential genetic risk factor for carbamazepine-induced DILI. Among all DILI cases analyzed, 33% of patients carried this allele, corresponding to an odds ratio (OR) of 7, which exceeds previously reported associations involving class II <italic toggle="yes">HLA</italic> alleles linked to lumiracoxib-induced DILI [<xref ref-type="bibr" rid="B42-ijms-27-00482">42</xref>]. Both carbamazepine-induced severe cutaneous adverse reactions and carbamazepine-related DILI share a unique amino acid residue (isoleucine at position 73) that defines a cryptic epitope specific to <italic toggle="yes">HLA</italic>-<italic toggle="yes">A31</italic> and <italic toggle="yes">HLA</italic>-<italic toggle="yes">A33</italic> molecules. Under physiological conditions, this epitope is normally concealed within the <italic toggle="yes">HLA</italic> structure; however, conformational changes in the antigen–peptide complex, such as dissociation of β<sub>2</sub>-microglobulin, may expose this residue and trigger an autoimmune response. <italic toggle="yes">HLA-A*33:01</italic> and <italic toggle="yes">HLA-A*33:03</italic> have been associated with DILI from several unrelated agents, suggesting a broader pattern of shared, immune-mediated susceptibility across different drugs. Nonetheless, in this study, the association with <italic toggle="yes">HLA-A*31:01</italic> did not achieve genome-wide significance, most likely due to the limited sample size [<xref ref-type="bibr" rid="B42-ijms-27-00482">42</xref>]. The authors propose that distinct mechanisms of antigen presentation may operate in the skin and liver, reflecting the liver’s central role in drug metabolism and the generation of reactive intermediates that can influence organ-specific immune activation [<xref ref-type="bibr" rid="B42-ijms-27-00482">42</xref>].</p></sec><sec id="sec3dot10-ijms-27-00482"><title>3.10. Allopurinol</title><p>In allopurinol-induced liver injury, <italic toggle="yes">HLA-B*58:01</italic> remains the most consistently identified risk allele, particularly among African and Asian populations. Recent data also suggest novel associations involving <italic toggle="yes">HLA-B*53:01</italic> and <italic toggle="yes">HLA-A*34:02</italic>, which were observed more frequently in African American patients. Haplotype analysis indicates that the effect of <italic toggle="yes">HLA-B*53:01</italic> may derive from its linkage disequilibrium with <italic toggle="yes">HLA-A*34:02</italic>, whereas <italic toggle="yes">HLA-B*58:01</italic> appears to act independently [<xref ref-type="bibr" rid="B43-ijms-27-00482">43</xref>]. These results not only confirm the established role of <italic toggle="yes">HLA-B*58:01</italic> in allopurinol liver involvement and cutaneous hypersensitivity but also highlight the possibility of ethnic-specific susceptibility haplotypes contributing to immune-mediated DILI. These observations underscore the critical role of <italic toggle="yes">HLA</italic> class I molecules in shaping drug-specific and tissue-selective immune responses, underscoring the need for integrated pharmacogenetic screening in high-risk populations [<xref ref-type="bibr" rid="B43-ijms-27-00482">43</xref>].</p></sec><sec id="sec3dot11-ijms-27-00482"><title>3.11. Ticlopinide</title><p><italic toggle="yes">HLA-A*33:03</italic> has been identified as a significant genetic risk factor for ticlopidine-induced DILI, particularly the severe cholestatic form, in Japanese individuals. This adverse reaction may be associated with the allele itself or with a specific haplotype encompassing <italic toggle="yes">HLA-A33:03</italic>, -<italic toggle="yes">B44:03, -C14:03</italic>, <italic toggle="yes">-DRB1*13:02</italic>, and -<italic toggle="yes">DQB1*06:04</italic>. Given the central role of <italic toggle="yes">HLA</italic> molecules in antigen presentation and immune activation, the observed association strongly supports an immune-mediated pathogenesis, which could explain the higher incidence of ticlopidine-induced liver injury reported in Japanese patients [<xref ref-type="bibr" rid="B44-ijms-27-00482">44</xref>]. Nicoletti et al. also reported a strong association between <italic toggle="yes">HLA-A*33:03</italic> and cholestatic DILI. <italic toggle="yes">HLA-A*33:03</italic> is relatively prevalent in East Asian populations, with an estimated carrier frequency of 10–15%, which may partially account for the ethnic variability observed in susceptibility to ticlopidine-induced hepatotoxicity [<xref ref-type="bibr" rid="B44-ijms-27-00482">44</xref>].</p></sec><sec id="sec3dot12-ijms-27-00482"><title>3.12. Antiepileptic Drugs</title><p><italic toggle="yes">HLA</italic>-<italic toggle="yes">B*53:01</italic> has emerged as a potential genetic risk factor for aromatic antiepileptic drug (AED)-induced liver injury, with the strongest association observed in phenytoin-related cases [<xref ref-type="bibr" rid="B44-ijms-27-00482">44</xref>,<xref ref-type="bibr" rid="B45-ijms-27-00482">45</xref>]. Children appear to be particularly vulnerable to antiepileptic DILI because they present a higher activity of CYP450 enzymes, which leads to an increased formation of hepatotoxic metabolites compared with adults [<xref ref-type="bibr" rid="B45-ijms-27-00482">45</xref>,<xref ref-type="bibr" rid="B46-ijms-27-00482">46</xref>].</p><p>Nicoletti et al. reported that 8 of 9 African American patients who developed phenytoin-induced hepatotoxicity carried this allele. These findings underscore the ethnic specificity of <italic toggle="yes">HLA</italic>-linked susceptibility patterns and the importance of population-based pharmacogenetic characterization in preventing severe adverse drug reactions [<xref ref-type="bibr" rid="B46-ijms-27-00482">46</xref>]. Supporting evidence comes from Thomas et al., who identified a similar association between <italic toggle="yes">HLA-B*53:01</italic> and raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) [<xref ref-type="bibr" rid="B45-ijms-27-00482">45</xref>,<xref ref-type="bibr" rid="B47-ijms-27-00482">47</xref>]. This overlap suggests that <italic toggle="yes">HLA-B*53:01</italic> may predispose to a shared immunopathogenic mechanism underlying both hepatic and systemic hypersensitivity reactions across structurally and pharmacologically unrelated drugs [<xref ref-type="bibr" rid="B45-ijms-27-00482">45</xref>,<xref ref-type="bibr" rid="B47-ijms-27-00482">47</xref>]. The recurrence of this allele in multiple immune-mediated toxicities reinforces its potential role as a class I <italic toggle="yes">HLA</italic> risk factor in idiosyncratic, immune-driven adverse drug responses.</p></sec><sec id="sec3dot13-ijms-27-00482"><title>3.13. Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors</title><p>This group of drugs, which includes infliximab, adalimumab, and etanercept, has revolutionized the management of autoimmune and inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Despite their clinical efficacy, these biologic agents have been increasingly associated with immune-mediated hepatic injury that may present with features resembling AIH. The precise mechanisms underlying these reactions remain unclear, but accumulating evidence suggests that <italic toggle="yes">HLA</italic>-restricted immune responses may predispose certain individuals to hepatotoxicity during anti-TNF therapy [<xref ref-type="bibr" rid="B48-ijms-27-00482">48</xref>].</p><p>Infliximab-induced DILI has been particularly associated with <italic toggle="yes">HLA</italic> class I alleles, most notably <italic toggle="yes">HLA-B*39:01,</italic> detected in 25% of DILI cases but absent among controls, despite its low frequency of only 2–2.3% in Caucasians [<xref ref-type="bibr" rid="B48-ijms-27-00482">48</xref>]. Among severe cases, defined by ALT levels greater than five times the upper limit of normal (ULN), the association was even stronger, with 30% carriage. All patients carrying <italic toggle="yes">HLA-B*39:01</italic> also possessed <italic toggle="yes">HLA-C*12:03,</italic> suggesting a haplotypic association. Although <italic toggle="yes">HLA-C*12:03</italic> was observed in a few control subjects, none carried both alleles, suggesting a specific <italic toggle="yes">HLA-B39:01–C12:03</italic> haplotype that may confer a distinct risk for infliximab-related hepatotoxicity [<xref ref-type="bibr" rid="B48-ijms-27-00482">48</xref>]. This haplotype, present in only ~1.3% of the general Caucasian population, was identified in 25% of DILI cases, representing a striking overrepresentation and supporting an immune-mediated mechanism underlying anti-TNF-associated liver injury [<xref ref-type="bibr" rid="B48-ijms-27-00482">48</xref>].</p></sec><sec id="sec3dot14-ijms-27-00482"><title>3.14. Herbal and Dietary Supplements (HDS)</title><p>Although conventional pharmaceuticals account for most cases of idiosyncratic DILI, similar immune-mediated mechanisms have been increasingly recognized in reactions triggered by herbal and dietary supplements (HDS). Green tea extract–related hepatotoxicity represents one of the most clearly defined examples of <italic toggle="yes">HLA</italic>-associated susceptibility [<xref ref-type="bibr" rid="B48-ijms-27-00482">48</xref>]. Hoofnagle et al. demonstrated a strong association between green tea–induced liver injury and the <italic toggle="yes">HLA-B*35:01</italic> allele, which parallels the class I-mediated immune responses observed with certain drugs, such as trimethoprim–sulfamethoxazole, phenytoin, and allopurinol [<xref ref-type="bibr" rid="B49-ijms-27-00482">49</xref>]. While <italic toggle="yes">HLA-B*35:01</italic> occurs in only 5–15% of the U.S. population, it was present in 72% of patients with confirmed green tea–related hepatotoxicity and in over 90% of highly probable cases. Carriers typically exhibited hepatocellular injury with rash or fever and moderate to severe disease accompanied by jaundice, closely resembling immune-mediated DILI phenotypes observed with pharmacological agents. In contrast, non-carriers showed atypical or chronic patterns of injury. Notably, the causality assessment in this study was performed before chemical and genetic analyses, suggesting that <italic toggle="yes">HLA</italic>-<italic toggle="yes">B*35:01</italic> may serve as a more objective and reproducible biomarker for causality than clinical judgment alone [<xref ref-type="bibr" rid="B49-ijms-27-00482">49</xref>]. These findings suggest that herbal supplements and drugs can share common <italic toggle="yes">HLA</italic>-restricted immune pathways leading to hepatocellular injury. Thus, <italic toggle="yes">HLA-B*35:01</italic> represents not only a risk marker for green tea–induced hepatotoxicity but also part of a broader spectrum of class I <italic toggle="yes">HLA</italic> alleles, including <italic toggle="yes">HLA-B*58:01</italic>, <italic toggle="yes">HLA-B*53:01</italic>, and <italic toggle="yes">HLA-A*31:01</italic>, that mediate drug- and supplement-induced immune liver injury [<xref ref-type="bibr" rid="B48-ijms-27-00482">48</xref>,<xref ref-type="bibr" rid="B49-ijms-27-00482">49</xref>].</p><table-wrap id="ijms-27-00482-t001" orientation="portrait" position="anchor"><object-id pub-id-type="pii">ijms-27-00482-t001_Table 1</object-id><label>Table 1</label><caption><p>Evidence on <italic toggle="yes">HLA</italic> association with DILI.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Drug</th><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA</italic>
</th><th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th></tr></thead><tbody><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">NSAID (diclofenac, ibuprofen)</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic toggle="yes">HLA-DRB1*04:03</italic><break/><italic toggle="yes">HLA-DQA1*03:01</italic><break/><italic toggle="yes">HLA-A*02:01</italic> (independent protective effect)<break/><italic toggle="yes">HLA</italic>-<italic toggle="yes">B*35:03l</italic></td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Bonkovsky, H.L. et al. [<xref ref-type="bibr" rid="B21-ijms-27-00482">21</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Minocycline</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-B*35:02</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Urban, T.J. et al. [<xref ref-type="bibr" rid="B25-ijms-27-00482">25</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nitrofurantoin</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic toggle="yes">HLA-DRB1*11:04</italic><break/><italic toggle="yes">HLA-A*01:01-B*08:01-C*07:01</italic> (liver injury following short-term nitrofurantoin therapy)</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Chalasani, N. et al. [<xref ref-type="bibr" rid="B26-ijms-27-00482">26</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Flucloxacillin</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-B*57:01</italic>
<break/>
<italic toggle="yes">HLA-B*57:03</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nicoletti, P. et al. [<xref ref-type="bibr" rid="B28-ijms-27-00482">28</xref>]<break/>Monshi, M.M. et al. [<xref ref-type="bibr" rid="B29-ijms-27-00482">29</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Amoxicillin–Clavulanate</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-DRB1*15:01</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Chalasani, N. et al. [<xref ref-type="bibr" rid="B30-ijms-27-00482">30</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic toggle="yes">HLA-DRB1*15:01–DQB1*06:02</italic><break/><italic toggle="yes">HLA-DRB1*07</italic> (protective effect)</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Donaldson, P.T. et al. [<xref ref-type="bibr" rid="B31-ijms-27-00482">31</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-DRB1*15:01–DRB5*01:01–DQB1*06:02</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hautekeete, M.L. et al. [<xref ref-type="bibr" rid="B32-ijms-27-00482">32</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Trimethoprim–sulfamethoxazole</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic toggle="yes">HLA-B*14:01</italic><break/><italic toggle="yes">HLA-B*35:01</italic> (African American subgroup)</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Li, Y.J. et al. [<xref ref-type="bibr" rid="B33-ijms-27-00482">33</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Azithromycin</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic toggle="yes">HLA-DQA1*03:01</italic><break/><italic toggle="yes">HLA-DQA1*03:01–DQB1*03:02</italic><break/>(stronger correlation with AZ-DILI than <italic toggle="yes">HLA-DQA1*03:01</italic> alone)</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Conlon, C. et al. [<xref ref-type="bibr" rid="B34-ijms-27-00482">34</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Antituberculosis</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic toggle="yes">HLA-C12:02–B52:01</italic><break/><italic toggle="yes">B*52:01</italic> allele demonstrated a stronger individual association than <italic toggle="yes">C*12:02</italic><break/><italic toggle="yes">HLA-DQB1*02:01</italic><break/><italic toggle="yes">HLA-DQA1*01:02</italic> (absence)<break/><italic toggle="yes">HLA-DQA1*01:03</italic><break/><italic toggle="yes">HLA-DQA1*03:01</italic></td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nicoletti, P. et al. [<xref ref-type="bibr" rid="B40-ijms-27-00482">40</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-DQB1*05</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Chen, R. et al. [<xref ref-type="bibr" rid="B41-ijms-27-00482">41</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Carbamazepine</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-A*31:01</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nicoletti, P. et al. [<xref ref-type="bibr" rid="B42-ijms-27-00482">42</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Allopurinol</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-B*58:01</italic>
<break/>
<italic toggle="yes">HLA-B*53:01</italic>
<break/>
<italic toggle="yes">HLA-A*34:02</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Fontana, R.J. et al. [<xref ref-type="bibr" rid="B43-ijms-27-00482">43</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ticlopidine</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-A*33:03</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hirata, K. et al. [<xref ref-type="bibr" rid="B44-ijms-27-00482">44</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Aromatic antiepileptic drugs (phenytoin)</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-B*53:01</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nicoletti, P. et al. [<xref ref-type="bibr" rid="B46-ijms-27-00482">46</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Raltegravir</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-B*53:01</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Thomas, M. et al. [<xref ref-type="bibr" rid="B47-ijms-27-00482">47</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Infliximab</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-B*39:01–C*12:03</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Bruno, C.D. et al. [<xref ref-type="bibr" rid="B48-ijms-27-00482">48</xref>]</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Green tea extract</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic toggle="yes">HLA-B*35:01</italic>
</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hoofnagle, J.H. et al. [<xref ref-type="bibr" rid="B49-ijms-27-00482">49</xref>]</td></tr></tbody></table></table-wrap></sec></sec><sec id="sec4-ijms-27-00482"><title>4. Further Challenges</title><p>The use of <italic toggle="yes">HLA</italic> in the diagnosis and prognosis of DILI raises challenges that will need to be resolved in the future. Understanding the mechanisms by which <italic toggle="yes">HLA</italic> alleles contribute to DILI and AIH remains incomplete. The frequency of <italic toggle="yes">HLA</italic> alleles varies significantly across different populations, limiting the generalizability of associations identified predominantly in European and Asian populations. Risk alleles identified in one population may not be clinically relevant in other populations. GWASs for DILI are largely conducted in European cohorts, limiting applicability to the global population. Cost-effectiveness studies show that <italic toggle="yes">HLA</italic> testing for most drugs associated with DILI does not meet the economic thresholds required for clinical implementation. One of the most significant limitations of <italic toggle="yes">HLA</italic> testing in DILI is the extremely low positive predictive value (PPV), despite high negative predictive value (NPV); most carriers of risk alleles will not develop hepatotoxicity, making preemptive genetic screening unrewarding for most drugs [<xref ref-type="bibr" rid="B50-ijms-27-00482">50</xref>,<xref ref-type="bibr" rid="B51-ijms-27-00482">51</xref>].</p><p>Future progress will require the development of complementary <italic toggle="yes">HLA</italic> biomarkers (cytokines, chemokines, markers of cellular activation), the implementation of preemptive <italic toggle="yes">HLA</italic> testing in expanded pharmacogenomic panels to improve PPV, standardization of next-generation sequencing (NGS) protocols and international reporting of <italic toggle="yes">HLA</italic> results, and large, ethnically diverse prospective cohorts to validate <italic toggle="yes">HLA</italic> associations. Integration of flow cytometry immunophenotyping to characterize the immune response in DILI will be necessary, as well as the development of standardized functional T lymphocyte tests for individualized risk assessment.</p><p>In clinical practice, decision-support algorithms should be developed to integrate <italic toggle="yes">HLA</italic> alongside clinical history, serological markers, and histology to differentiate DILI from AIH [<xref ref-type="bibr" rid="B52-ijms-27-00482">52</xref>]. Future approaches will require international collaborative efforts to standardize, validate, and develop integrative, personalized models to overcome the current limitations of isolated <italic toggle="yes">HLA</italic> genotyping.</p></sec><sec id="sec5-ijms-27-00482" sec-type="conclusions"><title>5. Conclusions</title><p>The involvement of the <italic toggle="yes">HLA</italic> system in the pathogenesis of DILI represents one of the most significant advances in modern pharmacogenetics. <italic toggle="yes">HLA</italic> molecules govern the interaction between the immune system and drug-derived antigens, determining whether these compounds are recognized as self or non-self. Specific <italic toggle="yes">HLA</italic> variants can therefore promote aberrant T lymphocyte activation, leading to hepatic inflammation, hepatocellular necrosis, and, in severe cases, acute liver failure. Understanding these immunogenetic mechanisms has substantial clinical and preventive relevance, as it enables the identification of individuals with genetic predisposition and the implementation of personalized therapeutic strategies. The integration of <italic toggle="yes">HLA</italic> genotyping into clinical practice could transform drug safety monitoring and prescribing practices, thereby reducing the incidence of severe hepatic adverse reactions. Consequently, the <italic toggle="yes">HLA</italic> system should be regarded not only as a genetic marker of susceptibility but also as a key tool in advancing predictive and precision medicine within hepatology.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.O., A.G. and T.L.P.; methodology, A.O., A.G. and T.L.P.; validation, A.O., A.G. and T.L.P.; formal analysis, A.O., A.G. and T.L.P.; investigation, A.O., A.G., Ș.A., A.M., B.M., H.Ş. and T.L.P.; resources, A.O., A.G., H.Ş. and T.L.P.; data curation, A.O., A.G. and T.L.P.; original draft preparation, A.O. writing—review and editing, A.O., A.G. and T.L.P.; visualization, A.O., A.G., Ș.A., A.M., B.M., H.Ş. and T.L.P.; supervision, A.G., H.Ş. and T.L.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" colspan="1" rowspan="1" valign="middle">AC-DILI</td><td align="left" colspan="1" rowspan="1" valign="middle">Amoxicillin-Clavulanate-Drug-Induced Liver Injury</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">AED</td><td align="left" colspan="1" rowspan="1" valign="middle">Aromatic Antiepileptic Drug</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">AIH</td><td align="left" colspan="1" rowspan="1" valign="middle">Autoimmune Hepatitis</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">ALT</td><td align="left" colspan="1" rowspan="1" valign="middle">Alanine Aminotransferase</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">ANA</td><td align="left" colspan="1" rowspan="1" valign="middle">Antinuclear Autoantibodies</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">ATLI</td><td align="left" colspan="1" rowspan="1" valign="middle">Antituberculosis Liver Injury</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">AZ-DILI</td><td align="left" colspan="1" rowspan="1" valign="middle">Azithromycin-Induced Drug-Induced Liver Injury</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">CI</td><td align="left" colspan="1" rowspan="1" valign="middle">Confidence Interval</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">DI-AIH</td><td align="left" colspan="1" rowspan="1" valign="middle">Drug-Induced Autoimmune Hepatitis</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">DI-AILD</td><td align="left" colspan="1" rowspan="1" valign="middle">Drug-Induced Autoimmune-Like Liver Disease</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">DILIN</td><td align="left" colspan="1" rowspan="1" valign="middle">Drug-Induced Liver Injury Network</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">DNA</td><td align="left" colspan="1" rowspan="1" valign="middle">Deoxyribonucleic Acid</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">DRESS</td><td align="left" colspan="1" rowspan="1" valign="middle">Drug Reaction with Eosinophilia and Systemic Symptoms</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">FasL</td><td align="left" colspan="1" rowspan="1" valign="middle">Fas Ligand</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">GWAS</td><td align="left" colspan="1" rowspan="1" valign="middle">Genome-Wide Association Studies</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">HDS </td><td align="left" colspan="1" rowspan="1" valign="middle">Herbal and Dietary Supplements</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">
<italic toggle="yes">HLA</italic>
</td><td align="left" colspan="1" rowspan="1" valign="middle">Human Leukocyte Antigen</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">IFN-γ</td><td align="left" colspan="1" rowspan="1" valign="middle">Interferon-γ</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">IM-DILI</td><td align="left" colspan="1" rowspan="1" valign="middle">Immune-Mediated Drug-Induced Liver Injury</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">MHC</td><td align="left" colspan="1" rowspan="1" valign="middle">Major Histocompatibility Complex</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">NGS</td><td align="left" colspan="1" rowspan="1" valign="middle">Next Generation Sequencing</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">NPV</td><td align="left" colspan="1" rowspan="1" valign="middle">Negative Predictive Value</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">NSAID</td><td align="left" colspan="1" rowspan="1" valign="middle">Non-Steroidal Anti-Inflammatory Drug</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">OR</td><td align="left" colspan="1" rowspan="1" valign="middle">Odds Ratio</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">PPV</td><td align="left" colspan="1" rowspan="1" valign="middle">Positive Predictive Value</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">RNA</td><td align="left" colspan="1" rowspan="1" valign="middle">Ribonucleic Acid</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">TB</td><td align="left" colspan="1" rowspan="1" valign="middle">Tuberculosis</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">Th</td><td align="left" colspan="1" rowspan="1" valign="middle">T helper</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">TMP–SMX</td><td align="left" colspan="1" rowspan="1" valign="middle">Trimethoprim-sulfamethoxazole</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">TNF-α</td><td align="left" colspan="1" rowspan="1" valign="middle">Tumor Necrosis Factor-alpha</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">ULN</td><td align="left" colspan="1" rowspan="1" valign="middle">Upper Limit of Normal</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">US</td><td align="left" colspan="1" rowspan="1" valign="middle">United States</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-ijms-27-00482"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Björnsson</surname><given-names>E.S.</given-names></name>
<name name-style="western"><surname>Suzuki</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kullak-Ublick</surname><given-names>G.A.</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>P.B.</given-names></name>
<name name-style="western"><surname>Devarbhavi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Merz</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>M.I.</given-names></name>
<name name-style="western"><surname>Kaplowitz</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Drug-Induced Liver Injury</article-title><source>Nat. Rev. Dis. Prim.</source><year>2019</year><volume>5</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1038/s41572-019-0105-0</pub-id><pub-id pub-id-type="pmid">31439850</pub-id></element-citation></ref><ref id="B2-ijms-27-00482"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Grama</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Aldea</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Burac</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Delean</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Boghitoiu</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Bulata</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Nitescu</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Ulmeanu</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Pop</surname><given-names>T.L.</given-names></name>
</person-group><article-title>Acute liver failure secondary to toxic exposure in children</article-title><source>Arch. Med. Sci.</source><year>2022</year><volume>18</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.5114/aoms.2019.87716</pub-id><pub-id pub-id-type="pmid">35154529</pub-id><pub-id pub-id-type="pmcid">PMC8826985</pub-id></element-citation></ref><ref id="B3-ijms-27-00482"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lee</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Drug-induced hepatotoxicity</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>349</volume><fpage>474</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1056/NEJMra021844</pub-id><pub-id pub-id-type="pmid">12890847</pub-id></element-citation></ref><ref id="B4-ijms-27-00482"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Katarey</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Verma</surname><given-names>S.</given-names></name>
</person-group><article-title>Drug-Induced Liver Injury</article-title><source>Clin. Med.</source><year>2016</year><volume>16</volume><fpage>S104</fpage><lpage>S109</lpage><pub-id pub-id-type="doi">10.7861/clinmedicine.16-6-s104</pub-id><pub-id pub-id-type="pmid">27956449</pub-id><pub-id pub-id-type="pmcid">PMC6329561</pub-id></element-citation></ref><ref id="B5-ijms-27-00482"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Schjøtt</surname><given-names>J.</given-names></name>
</person-group><article-title>Adverse Effects of Drugs and Toxins on the Liver</article-title><source>Liver Biopsy in Modern Medicine</source><person-group person-group-type="editor">
<name name-style="western"><surname>Mizuguchi</surname><given-names>Y.</given-names></name>
</person-group><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2011</year><fpage>137</fpage><lpage>162</lpage></element-citation></ref><ref id="B6-ijms-27-00482"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Aithal</surname><given-names>G.P.</given-names></name>
<name name-style="western"><surname>Björnsson</surname><given-names>E.S.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Sawle</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Arrese</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.X.</given-names></name>
<name name-style="western"><surname>Rockey</surname><given-names>D.C.</given-names></name>
<name name-style="western"><surname>Serrano</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Genetic risk factors in drug-induced liver injury: Evidence from genome-wide association studies</article-title><source>Hepatology</source><year>2017</year><volume>66</volume><fpage>1720</fpage><lpage>1731</lpage></element-citation></ref><ref id="B7-ijms-27-00482"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Rosenbaum</surname><given-names>S.</given-names></name>
</person-group><article-title>Developmental Pharmacokinetics in Pediatric Populations</article-title><source>J. Pediatr. Pharmacol. Ther.</source><year>2014</year><volume>19</volume><fpage>262</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.5863/1551-6776-19.4.262</pub-id><pub-id pub-id-type="pmid">25762871</pub-id><pub-id pub-id-type="pmcid">PMC4341411</pub-id></element-citation></ref><ref id="B8-ijms-27-00482"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Weber</surname><given-names>L.W.D.</given-names></name>
<name name-style="western"><surname>Boll</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Stampfl</surname><given-names>A.</given-names></name>
</person-group><article-title>Hepatotoxicity and mechanism of action of haloalkanes: Carbon tetrachloride as a toxicological model</article-title><source>Crit. Rev. Toxicol.</source><year>2003</year><volume>33</volume><fpage>105</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1080/713611034</pub-id><pub-id pub-id-type="pmid">12708612</pub-id></element-citation></ref><ref id="B9-ijms-27-00482"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mekuria</surname><given-names>A.N.</given-names></name>
<name name-style="western"><surname>Routledge</surname><given-names>M.N.</given-names></name>
<name name-style="western"><surname>Gong</surname><given-names>Y.Y.</given-names></name>
<name name-style="western"><surname>Sisay</surname><given-names>M.</given-names></name>
</person-group><article-title>Aflatoxins as a Risk Factor for Liver Cirrhosis: A Systematic Review and Meta-Analysis</article-title><source>BMC Pharmacol. Toxicol.</source><year>2020</year><volume>21</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.1186/s40360-020-00420-7</pub-id><pub-id pub-id-type="pmid">32487162</pub-id><pub-id pub-id-type="pmcid">PMC7268458</pub-id></element-citation></ref><ref id="B10-ijms-27-00482"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Castiella</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Zapata</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>M.I.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Drug-Induced Autoimmune Liver Disease: A Diagnostic Dilemma of an Increasingly Reported Disease</article-title><source>World J. Hepatol.</source><year>2014</year><volume>6</volume><fpage>160</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.4254/wjh.v6.i4.160</pub-id><pub-id pub-id-type="pmid">24799984</pub-id><pub-id pub-id-type="pmcid">PMC4009471</pub-id></element-citation></ref><ref id="B11-ijms-27-00482"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>European Association for the Study of the Liver</collab>
</person-group><article-title>EASL Clinical Practice Guidelines: Drug-Induced Liver Injury</article-title><source>J. Hepatol.</source><year>2019</year><volume>70</volume><fpage>1222</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.02.014</pub-id><pub-id pub-id-type="pmid">30926241</pub-id></element-citation></ref><ref id="B12-ijms-27-00482"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>M.I.</given-names></name>
<name name-style="western"><surname>Alonso</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>García-Cortes</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>García-Ruiz</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Benitez</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Fernández</surname><given-names>M.C.</given-names></name>
<name name-style="western"><surname>Pelaez</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Romero</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Corpas</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">HLA</italic> class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease</article-title><source>Hepatology</source><year>2004</year><volume>39</volume><fpage>1603</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/hep.20215</pub-id><pub-id pub-id-type="pmid">15185301</pub-id></element-citation></ref><ref id="B13-ijms-27-00482"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Appleyard</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Saraswati</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Gorard</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Autoimmune Hepatitis Triggered by Nitrofurantoin: A Case Series</article-title><source>J. Med. Case Rep.</source><year>2010</year><volume>4</volume><fpage>311</fpage><pub-id pub-id-type="doi">10.1186/1752-1947-4-311</pub-id><pub-id pub-id-type="pmid">20863377</pub-id><pub-id pub-id-type="pmcid">PMC2955056</pub-id></element-citation></ref><ref id="B14-ijms-27-00482"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Mu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>
</person-group><article-title>Liver Injury Induced by Carbon Tetrachloride in Mice Is Prevented by the Antioxidant Capacity of Anji White Tea Polyphenols</article-title><source>Antioxidants</source><year>2019</year><volume>8</volume><elocation-id>64</elocation-id><pub-id pub-id-type="doi">10.3390/antiox8030064</pub-id><pub-id pub-id-type="pmid">30875793</pub-id><pub-id pub-id-type="pmcid">PMC6466528</pub-id></element-citation></ref><ref id="B15-ijms-27-00482"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kenna</surname><given-names>J.G.</given-names></name>
<name name-style="western"><surname>Neuberger</surname><given-names>J.</given-names></name>
</person-group><article-title>Immune-mediated drug-induced liver injury in humans</article-title><source>Semin. Liver Dis.</source><year>2010</year><volume>30</volume><fpage>66</fpage><lpage>74</lpage></element-citation></ref><ref id="B16-ijms-27-00482"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Pohl</surname><given-names>L.R.</given-names></name>
<name name-style="western"><surname>Thomassen</surname><given-names>D.G.</given-names></name>
<name name-style="western"><surname>Pumford</surname><given-names>N.R.</given-names></name>
<name name-style="western"><surname>Butler</surname><given-names>L.E.</given-names></name>
<name name-style="western"><surname>Satoh</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Ferrans</surname><given-names>V.J.</given-names></name>
<name name-style="western"><surname>Perrone</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Martin</surname><given-names>B.M.</given-names></name>
<name name-style="western"><surname>Martin</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Hapten Carrier Conjugates Associated with Halothane Hepatitis</article-title><source>Drug-Induced Liver Injury</source><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>1991</year><volume>Volume 283</volume><fpage>111</fpage><lpage>120</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/978-1-4684-5877-0_12</pub-id><pub-id pub-id-type="pmid">2068977</pub-id></element-citation></ref><ref id="B17-ijms-27-00482"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Björnsson</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Talwalkar</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Treeprasertsuk</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Kamath</surname><given-names>P.S.</given-names></name>
<name name-style="western"><surname>Takahashi</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Sanderson</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Neuhauser</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Lindor</surname><given-names>K.</given-names></name>
</person-group><article-title>Drug-Induced Autoimmune Hepatitis: Clinical Characteristics and Prognosis</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><fpage>2040</fpage><lpage>2048</lpage><pub-id pub-id-type="doi">10.1002/hep.23588</pub-id><pub-id pub-id-type="pmid">20512992</pub-id></element-citation></ref><ref id="B18-ijms-27-00482"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>de Boer</surname><given-names>Y.S.</given-names></name>
<name name-style="western"><surname>Kosinski</surname><given-names>A.S.</given-names></name>
<name name-style="western"><surname>Urban</surname><given-names>T.J.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Long</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Kleiner</surname><given-names>D.E.</given-names></name>
<name name-style="western"><surname>Hoofnagle</surname><given-names>J.H.</given-names></name>
<collab>Drug-Induced Liver Injury Network</collab>
</person-group><article-title>Features of Autoimmune Hepatitis in Patients with Drug-Induced Liver Injury</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2017</year><volume>15</volume><fpage>103</fpage><lpage>112.e2</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2016.05.043</pub-id><pub-id pub-id-type="pmid">27311619</pub-id><pub-id pub-id-type="pmcid">PMC5370577</pub-id></element-citation></ref><ref id="B19-ijms-27-00482"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dara</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Z.X.</given-names></name>
<name name-style="western"><surname>Kaplowitz</surname><given-names>N.</given-names></name>
</person-group><article-title>Mechanisms of Adaptation and Progression in Idiosyncratic Drug-Induced Liver Injury: Clinical Implications</article-title><source>Liver Int.</source><year>2016</year><volume>36</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1111/liv.12988</pub-id><pub-id pub-id-type="pmid">26484420</pub-id><pub-id pub-id-type="pmcid">PMC4718752</pub-id></element-citation></ref><ref id="B20-ijms-27-00482"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Dara</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Z.-X.</given-names></name>
<name name-style="western"><surname>Kaplowitz</surname><given-names>N.</given-names></name>
</person-group><article-title>Pathogenesis of Idiosyncratic Drug-Induced Liver Injury</article-title><source>Liver Pathophysiology</source><person-group person-group-type="editor">
<name name-style="western"><surname>Muriel</surname><given-names>P.</given-names></name>
</person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year><fpage>87</fpage><lpage>100</lpage></element-citation></ref><ref id="B21-ijms-27-00482"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bonkovsky</surname><given-names>H.L.</given-names></name>
<name name-style="western"><surname>Ghabril</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Dellinger</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Daly</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Aithal</surname><given-names>G.P.</given-names></name>
<name name-style="western"><surname>Phillips</surname><given-names>E.J.</given-names></name>
<etal/>
</person-group><article-title>Drug-Induced Liver Injury (DILI) Ascribed to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the USA—Update with Genetic Correlations</article-title><source>Liver Int.</source><year>2024</year><volume>44</volume><fpage>1409</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1111/liv.15892</pub-id><pub-id pub-id-type="pmid">38451034</pub-id><pub-id pub-id-type="pmcid">PMC12009671</pub-id></element-citation></ref><ref id="B22-ijms-27-00482"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zoubek</surname><given-names>M.E.</given-names></name>
<name name-style="western"><surname>González-Jimenez</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Medina-Cáliz</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Robles-Díaz</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hernandez</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Romero-Gómez</surname><given-names>M.</given-names></name>
</person-group><article-title>High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2018</year><volume>16</volume><fpage>292</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2017.07.037</pub-id><pub-id pub-id-type="pmid">28782674</pub-id></element-citation></ref><ref id="B23-ijms-27-00482"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gui</surname><given-names>M.Z.</given-names></name>
<name name-style="western"><surname>Ni</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Yin</surname><given-names>X.D.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Z.L.</given-names></name>
</person-group><article-title>Ibuprofen-Induced Stevens–Johnson Syndrome and Liver Injury in Children: A Case Report</article-title><source>Transl. Pediatr.</source><year>2021</year><volume>10</volume><fpage>1737</fpage><lpage>1742</lpage><comment>Erratum in <italic toggle="yes">Transl. Pediatr.</italic> <bold>2021</bold>, <italic toggle="yes">10</italic>, 2881</comment><pub-id pub-id-type="doi">10.21037/tp-21-8</pub-id><pub-id pub-id-type="pmid">34295789</pub-id><pub-id pub-id-type="pmcid">PMC8261580</pub-id></element-citation></ref><ref id="B24-ijms-27-00482"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>H.L.</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Stolz</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Talwalkar</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Reddy</surname><given-names>K.R.</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>P.B.</given-names></name>
<name name-style="western"><surname>Navarro</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Features and Outcomes of 899 Patients with Drug-Induced Liver Injury: The DILIN Prospective Study</article-title><source>Gastroenterology</source><year>2015</year><volume>148</volume><fpage>1340</fpage><lpage>1352.e7</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.03.006</pub-id><pub-id pub-id-type="pmid">25754159</pub-id><pub-id pub-id-type="pmcid">PMC4446235</pub-id></element-citation></ref><ref id="B25-ijms-27-00482"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Urban</surname><given-names>T.J.</given-names></name>
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Serrano</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Stolz</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Daly</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Aithal</surname><given-names>G.P.</given-names></name>
<name name-style="western"><surname>Dillon</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Navarro</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Odin</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Minocycline Hepatotoxicity: Clinical Characterization and Identification of <italic toggle="yes">HLA</italic>-B*35:02 as a Risk Factor</article-title><source>J. Hepatol.</source><year>2017</year><volume>67</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.03.010</pub-id><pub-id pub-id-type="pmid">28323125</pub-id><pub-id pub-id-type="pmcid">PMC5634615</pub-id></element-citation></ref><ref id="B26-ijms-27-00482"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name>
<name name-style="western"><surname>Dellinger</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Navarro</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Phillips</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Lammert</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Clinical Features, Outcomes, and <italic toggle="yes">HLA</italic> Risk Factors Associated with Nitrofurantoin-Induced Liver Injury</article-title><source>J. Hepatol.</source><year>2023</year><volume>78</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2022.09.010</pub-id><pub-id pub-id-type="pmid">36152763</pub-id><pub-id pub-id-type="pmcid">PMC9852026</pub-id></element-citation></ref><ref id="B27-ijms-27-00482"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>van Gerven</surname><given-names>N.M.</given-names></name>
<name name-style="western"><surname>de Boer</surname><given-names>Y.S.</given-names></name>
<name name-style="western"><surname>Zwiers</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Verwer</surname><given-names>B.J.</given-names></name>
<name name-style="western"><surname>Drenth</surname><given-names>J.P.</given-names></name>
<name name-style="western"><surname>van Hoek</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>van Erpecum</surname><given-names>K.J.</given-names></name>
<name name-style="western"><surname>Beuers</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>van Buuren</surname><given-names>H.R.</given-names></name>
<name name-style="western"><surname>den Ouden</surname><given-names>J.W.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">HLA</italic>-DRB103:01 and <italic toggle="yes">HLA</italic>-DRB104:01 Modify the Presentation and Outcome in Autoimmune Hepatitis Type-1</article-title><source>Genes Immun.</source><year>2015</year><volume>16</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/gene.2014.82</pub-id><pub-id pub-id-type="pmid">25611558</pub-id></element-citation></ref><ref id="B28-ijms-27-00482"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Aithal</surname><given-names>G.P.</given-names></name>
<name name-style="western"><surname>Chamberlain</surname><given-names>T.C.</given-names></name>
<name name-style="western"><surname>Coulthard</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Alshabeeb</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Grove</surname><given-names>J.I.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Bjornsson</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Dillon</surname><given-names>J.F.</given-names></name>
<name name-style="western"><surname>Hallberg</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles</article-title><source>Clin. Pharmacol. Ther.</source><year>2019</year><volume>106</volume><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1002/cpt.1375</pub-id><pub-id pub-id-type="pmid">30661239</pub-id></element-citation></ref><ref id="B29-ijms-27-00482"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Monshi</surname><given-names>M.M.</given-names></name>
<name name-style="western"><surname>Faulkner</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Gibson</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Jenkins</surname><given-names>R.E.</given-names></name>
<name name-style="western"><surname>Farrell</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Earnshaw</surname><given-names>C.J.</given-names></name>
<name name-style="western"><surname>Alfirevic</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Cederbrant</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Daly</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>French</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Human Leukocyte Antigen (<italic toggle="yes">HLA</italic>)-B*57:01-Restricted Activation of Drug-Specific T Cells Provides the Immunological Basis for Flucloxacillin-Induced Liver Injury</article-title><source>Hepatology</source><year>2013</year><volume>57</volume><fpage>727</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1002/hep.26077</pub-id><pub-id pub-id-type="pmid">22987284</pub-id></element-citation></ref><ref id="B30-ijms-27-00482"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Björnsson</surname><given-names>E.</given-names></name>
</person-group><article-title>Risk Factors for Idiosyncratic Drug-Induced Liver Injury</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>2246</fpage><lpage>2259</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.04.001</pub-id><pub-id pub-id-type="pmid">20394749</pub-id><pub-id pub-id-type="pmcid">PMC3157241</pub-id></element-citation></ref><ref id="B31-ijms-27-00482"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Donaldson</surname><given-names>P.T.</given-names></name>
<name name-style="western"><surname>Daly</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Henderson</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Graham</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Pirmohamed</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Bernal</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Day</surname><given-names>C.P.</given-names></name>
<name name-style="western"><surname>Aithal</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Human Leucocyte Antigen Class II Genotype in Susceptibility and Resistance to Co-Amoxiclav-Induced Liver Injury</article-title><source>J. Hepatol.</source><year>2010</year><volume>53</volume><fpage>1049</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.05.033</pub-id><pub-id pub-id-type="pmid">20800921</pub-id></element-citation></ref><ref id="B32-ijms-27-00482"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hautekeete</surname><given-names>M.L.</given-names></name>
<name name-style="western"><surname>Horsmans</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Van Waeyenberge</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Demanet</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Henrion</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Verbist</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Brenard</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Sempoux</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Michielsen</surname><given-names>P.P.</given-names></name>
<name name-style="western"><surname>Yap</surname><given-names>P.S.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">HLA</italic> Association of Amoxicillin-Clavulanate–Induced Hepatitis</article-title><source>Gastroenterology</source><year>1999</year><volume>117</volume><fpage>1181</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(99)70404-X</pub-id><pub-id pub-id-type="pmid">10535882</pub-id></element-citation></ref><ref id="B33-ijms-27-00482"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name>
<name name-style="western"><surname>Phillips</surname><given-names>E.J.</given-names></name>
<name name-style="western"><surname>Dellinger</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Schutte</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Ostrov</surname><given-names>D.A.</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>P.B.</given-names></name>
<name name-style="western"><surname>Stolz</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Human Leukocyte Antigen B<italic toggle="yes">14:01 and B</italic>35:01 Are Associated with Trimethoprim-Sulfamethoxazole Induced Liver Injury</article-title><source>Hepatology</source><year>2021</year><volume>73</volume><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1002/hep.31258</pub-id><pub-id pub-id-type="pmid">32270503</pub-id><pub-id pub-id-type="pmcid">PMC7544638</pub-id></element-citation></ref><ref id="B34-ijms-27-00482"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Conlon</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name>
<name name-style="western"><surname>Ahmad</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Ghabril</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hayashi</surname><given-names>P.H.</given-names></name>
<name name-style="western"><surname>Kleiner</surname><given-names>D.E.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>W.M.</given-names></name>
<name name-style="western"><surname>Navarro</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Clinical Characteristics and <italic toggle="yes">HLA</italic> Associations of Azithromycin-Induced Liver Injury</article-title><source>Aliment. Pharmacol. Ther.</source><year>2024</year><volume>60</volume><fpage>787</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1111/apt.18160</pub-id><pub-id pub-id-type="pmid">38988034</pub-id><pub-id pub-id-type="pmcid">PMC11587661</pub-id></element-citation></ref><ref id="B35-ijms-27-00482"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ferrer</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Amelio</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Ballarín</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Sabaté</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Vidal</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Rottenkolber</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Schmiedl</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Laporte</surname><given-names>J.-R.</given-names></name>
<name name-style="western"><surname>Ibanez</surname><given-names>L.</given-names></name>
<collab>PROTECT Work Package 2</collab>
</person-group><article-title>Systematic Review and Meta-Analysis: Macrolides- and Amoxicillin/Clavulanate-Induced Acute Liver Injury</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2016</year><volume>119</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/bcpt.12550</pub-id><pub-id pub-id-type="pmid">26707367</pub-id></element-citation></ref><ref id="B36-ijms-27-00482"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Woodhead</surname><given-names>J.L.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Oldach</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>MacLauchlin</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Fernandes</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>P.B.</given-names></name>
<name name-style="western"><surname>Siler</surname><given-names>S.Q.</given-names></name>
<name name-style="western"><surname>Howell</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling</article-title><source>Pharm. Res.</source><year>2019</year><volume>36</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1007/s11095-019-2582-y</pub-id><pub-id pub-id-type="pmid">30734107</pub-id><pub-id pub-id-type="pmcid">PMC6373306</pub-id></element-citation></ref><ref id="B37-ijms-27-00482"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Aithal</surname><given-names>G.P.</given-names></name>
<name name-style="western"><surname>Bjornsson</surname><given-names>E.S.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Sawle</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Arrese</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.X.</given-names></name>
<name name-style="western"><surname>Bondon-Guitton</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Hayashi</surname><given-names>P.H.</given-names></name>
<name name-style="western"><surname>Bessone</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in <italic toggle="yes">HLA</italic> and Other Genes in a Genome-Wide Association Study</article-title><source>Gastroenterology</source><year>2017</year><volume>152</volume><fpage>1078</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.12.016</pub-id><pub-id pub-id-type="pmid">28043905</pub-id><pub-id pub-id-type="pmcid">PMC5367948</pub-id></element-citation></ref><ref id="B38-ijms-27-00482"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Choi</surname><given-names>S.H.</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>E.Y.</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name>
</person-group><article-title>Systemic Use of Fluoroquinolone in Children</article-title><source>Korean J. Pediatr.</source><year>2013</year><volume>56</volume><fpage>196</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.3345/kjp.2013.56.5.196</pub-id><pub-id pub-id-type="pmid">23741232</pub-id><pub-id pub-id-type="pmcid">PMC3668199</pub-id></element-citation></ref><ref id="B39-ijms-27-00482"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ahmad</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Dellinger</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.X.</given-names></name>
<name name-style="western"><surname>Ghabril</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Navarro</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Choi</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Hayashi</surname><given-names>P.H.</given-names></name>
<name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Clinical and <italic toggle="yes">HLA</italic> Associations of Fluoroquinolone-Induced Liver Injury: Results from the Drug-Induced Liver Injury Network</article-title><source>Am. J. Gastroenterol.</source><year>2026</year><volume>151</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000003457</pub-id><pub-id pub-id-type="pmcid">PMC12353811</pub-id><pub-id pub-id-type="pmid">40207808</pub-id></element-citation></ref><ref id="B40-ijms-27-00482"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Devarbhavi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Goel</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Venkatesan</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Eapen</surname><given-names>C.E.</given-names></name>
<name name-style="western"><surname>Grove</surname><given-names>J.I.</given-names></name>
<name name-style="western"><surname>Zafer</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Björnsson</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>M.I.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
<etal/>
</person-group><article-title>Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens</article-title><source>Clin. Pharmacol. Ther.</source><year>2021</year><volume>109</volume><fpage>1125</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1002/cpt.2100</pub-id><pub-id pub-id-type="pmid">33135175</pub-id></element-citation></ref><ref id="B41-ijms-27-00482"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Lv</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhan</surname><given-names>S.Y.</given-names></name>
</person-group><article-title>The Association between <italic toggle="yes">HLA</italic>-DQB1 Polymorphism and Antituberculosis Drug-Induced Liver Injury: A Case-Control Study</article-title><source>J. Clin. Pharm. Ther.</source><year>2015</year><volume>40</volume><fpage>110</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/jcpt.12211</pub-id><pub-id pub-id-type="pmid">25250564</pub-id></element-citation></ref><ref id="B42-ijms-27-00482"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Barrett</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>McEvoy</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Daly</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Aithal</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>M.I.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Wadelius</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hallberg</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Stephens</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Shared Genetic Risk Factors across Carbamazepine-Induced Hypersensitivity Reactions</article-title><source>Clin. Pharmacol. Ther.</source><year>2019</year><volume>106</volume><fpage>1028</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1002/cpt.1493</pub-id><pub-id pub-id-type="pmid">31066027</pub-id><pub-id pub-id-type="pmcid">PMC7156285</pub-id></element-citation></ref><ref id="B43-ijms-27-00482"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Fontana</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name>
<name name-style="western"><surname>Phillips</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Saeed</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Kleiner</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Hoofnagle</surname><given-names>J.</given-names></name>
<collab>Drug Induced Liver Injury Network</collab>
</person-group><article-title>Allopurinol Hepatotoxicity Is Associated with Human Leukocyte Antigen Class I Alleles</article-title><source>Liver Int.</source><year>2021</year><volume>41</volume><fpage>1884</fpage><lpage>1893</lpage><pub-id pub-id-type="doi">10.1111/liv.14903</pub-id><pub-id pub-id-type="pmid">33899326</pub-id><pub-id pub-id-type="pmcid">PMC8286350</pub-id></element-citation></ref><ref id="B44-ijms-27-00482"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hirata</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Takagi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Yamamoto</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Matsumoto</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Nishiya</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Mori</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Shimizu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Masumoto</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Okutani</surname><given-names>Y.</given-names></name>
</person-group><article-title>Ticlopidine-Induced Hepatotoxicity Is Associated with Specific Human Leukocyte Antigen Genomic Subtypes in Japanese Patients: A Preliminary Case-Control Study</article-title><source>Pharmacogenomics J.</source><year>2008</year><volume>8</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/sj.tpj.6500442</pub-id><pub-id pub-id-type="pmid">17339877</pub-id></element-citation></ref><ref id="B45-ijms-27-00482"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Maris</surname><given-names>B.R.</given-names></name>
<name name-style="western"><surname>Grama</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Pop</surname><given-names>T.L.</given-names></name>
</person-group><article-title>Drug-Induced Liver Injury—Pharmacological Spectrum among Children</article-title><source>Int. J. Mol. Sci.</source><year>2025</year><volume>26</volume><elocation-id>2006</elocation-id><pub-id pub-id-type="doi">10.3390/ijms26052006</pub-id><pub-id pub-id-type="pmid">40076629</pub-id><pub-id pub-id-type="pmcid">PMC11901067</pub-id></element-citation></ref><ref id="B46-ijms-27-00482"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nicoletti</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Dellinger</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Phillips</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Chalasani</surname><given-names>N.</given-names></name>
<collab>for the Drug Induced Liver Injury Network (DILIN) investigators</collab>
</person-group><article-title><italic toggle="yes">HLA</italic>-B*53:01 Is a Significant Risk Factor of Liver Injury due to Phenytoin and Other Antiepileptic Drugs in African Americans</article-title><source>Am. J. Gastroenterol.</source><year>2024</year><volume>119</volume><fpage>200</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000002454</pub-id><pub-id pub-id-type="pmid">37552102</pub-id><pub-id pub-id-type="pmcid">PMC10841235</pub-id></element-citation></ref><ref id="B47-ijms-27-00482"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Thomas</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hopkins</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Duffy</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Loulergue</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Ripamonti</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Ostrov</surname><given-names>D.A.</given-names></name>
<name name-style="western"><surname>Phillips</surname><given-names>E.</given-names></name>
</person-group><article-title>Association of the <italic toggle="yes">HLA</italic>-B*53:01 Allele with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome during Treatment of HIV Infection with Raltegravir</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>64</volume><fpage>1198</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1093/cid/cix096</pub-id><pub-id pub-id-type="pmid">28369189</pub-id><pub-id pub-id-type="pmcid">PMC5399947</pub-id></element-citation></ref><ref id="B48-ijms-27-00482"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bruno</surname><given-names>C.D.</given-names></name>
<name name-style="western"><surname>Fremd</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Church</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Daly</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Aithal</surname><given-names>G.P.</given-names></name>
<name name-style="western"><surname>Björnsson</surname><given-names>E.S.</given-names></name>
<name name-style="western"><surname>Larrey</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>P.B.</given-names></name>
<name name-style="western"><surname>Chow</surname><given-names>C.R.</given-names></name>
</person-group><article-title><italic toggle="yes">HLA</italic> Associations with Infliximab-Induced Liver Injury</article-title><source>Pharmacogenomics J.</source><year>2020</year><volume>20</volume><fpage>681</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1038/s41397-020-0159-0</pub-id><pub-id pub-id-type="pmid">32024945</pub-id></element-citation></ref><ref id="B49-ijms-27-00482"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hoofnagle</surname><given-names>J.H.</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>H.L.</given-names></name>
<name name-style="western"><surname>Phillips</surname><given-names>E.J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name>
<name name-style="western"><surname>Ahmad</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Barnhart</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Durazo</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Khan</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">HLA</italic>-B*35:01 and Green Tea-Induced Liver Injury</article-title><source>Hepatology</source><year>2021</year><volume>73</volume><fpage>2484</fpage><lpage>2493</lpage><pub-id pub-id-type="doi">10.1002/hep.31538</pub-id><pub-id pub-id-type="pmid">32892374</pub-id><pub-id pub-id-type="pmcid">PMC8052949</pub-id></element-citation></ref><ref id="B50-ijms-27-00482"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Clare</surname><given-names>K.E.</given-names></name>
<name name-style="western"><surname>Miller</surname><given-names>M.H.</given-names></name>
<name name-style="western"><surname>Dillon</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?</article-title><source>Curr. Hepatol. Rep.</source><year>2017</year><volume>16</volume><fpage>258</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1007/s11901-017-0363-9</pub-id><pub-id pub-id-type="pmid">28856081</pub-id><pub-id pub-id-type="pmcid">PMC5556130</pub-id></element-citation></ref><ref id="B51-ijms-27-00482"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Manson</surname><given-names>L.E.N.</given-names></name>
<name name-style="western"><surname>Swen</surname><given-names>J.J.</given-names></name>
<name name-style="western"><surname>Guchelaar</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Diagnostic Test Criteria for <italic toggle="yes">HLA</italic> Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable <italic toggle="yes">HLA</italic> Recommendations in CPIC and DPWG Guidelines</article-title><source>Front. Pharmacol.</source><year>2020</year><volume>11</volume><elocation-id>567048</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2020.567048</pub-id><pub-id pub-id-type="pmid">33071783</pub-id><pub-id pub-id-type="pmcid">PMC7538700</pub-id></element-citation></ref><ref id="B52-ijms-27-00482"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Aithal</surname><given-names>G.P.</given-names></name>
<name name-style="western"><surname>de Boer</surname><given-names>Y.S.</given-names></name>
<name name-style="western"><surname>Liberal</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Gerbes</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Regev</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Terziroli Beretta-Piccoli</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Schramm</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Kleiner</surname><given-names>D.E.</given-names></name>
<name name-style="western"><surname>De Martin</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>IAIHG and EASL DHILI Consortium. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report</article-title><source>J. Hepatol.</source><year>2023</year><volume>79</volume><fpage>853</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.04.033</pub-id><pub-id pub-id-type="pmid">37164270</pub-id><pub-id pub-id-type="pmcid">PMC10735171</pub-id></element-citation></ref></ref-list></back></article>